Drugs / BG2109
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05738382 | Aug 2023 → Jun 2024 | — | Bio Genuine (Shanghai) Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05894135 | Jul 2023 → Jun 2024 | endometriosis of pelvic peritoneum | Bio Genuine (Shanghai) Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05620355 | Dec 2022 → May 2024 | leiomyoma | Bio Genuine (Shanghai) Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05894135 ↗ |
| Route | Oral | “for oral administration” NCT05620355 ↗ |